Elevated Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 Level in Patients with Acute Coronary Syndrome (ACS): A Biomarker of Disease Severity and Outcome
Table 3
Clinical outcomes in patients with plasma percentile vs. patients with plasma percentiles.
Plasma percentile ()
Plasma percentiles ()
value
MACE day 30
7 (11.5)
12 (20.0)
0.21
CVA day 30
0 (0.0)
5 (8.3)
0.02
MI day 30
0 (0.0)
2 (3.3)
0.15
Mortality day 30
0 (0.0)
1 (1.7)
0.36
Cardiac catheterization day 30
7 (11.7)
10 (16.7)
0.60
MACE month 6
8 (13.1)
13 (21.7)
0.23
Stroke month 6
0 (0.0)
5 (8.3)
0.02
Recurrent MI month 6
0 (0.0)
4 (6.7)
0.04
Mortality month 6
0 (0.0)
1 (1.7)
0.36
Cardiac catheterization month 6
8 (13.1)
11 (18.3)
0.43
ACS
27 (44.3)
32 (53.3)
0.36
STEMI
15 (24.6)
7 (11.7)
0.10
NSTEMI
3 (4.9)
5 (8.3)
0.45
Single vessel disease
13 (48.1)
6 (19.4)
0.001
Two vessel disease
10 (37.0)
6 (19.4)
Three vessel disease
4 (14.8)
19 (61.3)
99th percentile of sTREM-1 in healthy control defined as 423 pg/ml.
